Systemic antifungal agents used to treat onychomycosis

被引：17

作者：

Katz, HI ^{[1
]}

机构：

[1] Minnesota Clin Study Ctr, Fridley, MN 55432 USA

来源：

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY | 1998年 / 38卷 / 05期

关键词：

D O I：

10.1016/S0190-9622(98)70484-0

中图分类号：

R75 [皮肤病学与性病学];

学科分类号：

100206 ;

摘要：

引用

页码：S48 / S52

页数：5

共 35 条

[1] KETOCONAZOLE AND FLUCONAZOLE DRUG-INTERACTIONS [J].

BACIEWICZ, AM ;

BACIEWICZ, FA .

ARCHIVES OF INTERNAL MEDICINE, 1993, 153 (17) :1970-1976

[2] PROBABLE INTERACTION BETWEEN FLUOXETINE AND ITRACONAZOLE [J].

BLACK, PN .

ANNALS OF PHARMACOTHERAPY, 1995, 29 (10) :1048-1049

[3] INCREASED GASTRIC PH AND THE BIOAVAILABILITY OF FLUCONAZOLE AND KETOCONAZOLE [J].

BLUM, RA ;

DANDREA, DT ;

FLORENTINO, BM ;

WILTON, JH ;

HILLIGOSS, DM ;

GARDNER, MJ ;

HENRY, EB ;

GOLDSTEIN, H ;

SCHENTAG, JJ .

ANNALS OF INTERNAL MEDICINE, 1991, 114 (09) :755-757

[4]

Bohme A, 1995, ANN HEMATOL, V71, P311, DOI 10.1007/BF01697985

[5] CLINICAL PEARL - SYSTEMIC ANTIFUNGAL DRUGS AND DRUG-INTERACTIONS [J].

BRODELL, RT ;

ELEWSKI, BE .

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 1995, 33 (02) :259-260

[6] EFFECT OF KETOCONAZOLE ON HEPATIC OXIDATIVE DRUG-METABOLISM [J].

BROWN, MW ;

MALDONADO, AL ;

MEREDITH, CG ;

SPEEG, KV .

CLINICAL PHARMACOLOGY & THERAPEUTICS, 1985, 37 (03) :290-297

[7] IN-VIVO INTERACTION OF KETOCONAZOLE AND SUCRALFATE IN HEALTHY-VOLUNTEERS [J].

CARVER, PL ;

BERARDI, RR ;

KNAPP, MJ ;

RIDER, JM ;

KAUFFMAN, CA ;

BRADLEY, SF ;

ATASSI, M .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1994, 38 (02) :326-329

[8]

COMO JA, 1994, NEW ENGL J MED, V330, P263, DOI 10.1056/NEJM199401273300407

[9] CLINICAL PHARMACOKINETICS OF KETOCONAZOLE [J].

DANESHMEND, TK ;

WARNOCK, DW .

CLINICAL PHARMACOKINETICS, 1988, 14 (01) :13-34

[10] COADMINISTRATION OF RIFAMPIN AND ITRACONAZOLE LEADS TO UNDETECTABLE LEVELS OF SERUM ITRACONAZOLE [J].

DRAYTON, J ;

DICKINSON, G ;

RINALDI, MG .

CLINICAL INFECTIOUS DISEASES, 1994, 18 (02) :266-266

← 1 2 3 4 →